Towards Healthcare
Biological Inactivated Vaccine Market Size Reach USD 1.57 Bn by 2034

Biological Inactivated Vaccine Market to Triple by 2034 Demand Grows Across Topical & Transdermal Segments

According to market projections, the global biological inactivated vaccine market, valued at USD 0.95 billion in 2024, is anticipated to reach USD 1.57 billion by 2034, growing at a CAGR of 5.14% over the next decade.The rising prevalence of infectious disorders and the growing research and development activities bolster market growth. The presence of key players and the availability of state-of-the-art research and development facilities contribute to North America’s dominance.

Content

  • Insight Code: 5932
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The biological inactivated vaccine market is projected to reach USD 1.57 billion by 2034, growing at a CAGR of 5.14% from 2025 to 2034.

North America is leading the biological inactivated vaccine market due to the availability of state-of-the-art research and development facilities, the presence of key players, and favorable government support.

The biological inactivated vaccine market includes seven segments including by vaccine type, by application disease type, by end-user, by route of administration, by distribution channel, by technology production process, and by region.

Some key players include GlaxoSmithKline, Pfizer, and Merck.

The polio vaccine was the first inactivated vaccine that was both safe and effective, developed by Jonas Salk in the 1950s.

World Health Organization, Centers for Disease Control and Prevention, GPEI, The Observatory of Economic Complexity
Any Questions